|Bid||602.00 x 900|
|Ask||616.00 x 1000|
|Day's range||605.00 - 623.20|
|52-week range||441.00 - 686.62|
|Beta (5Y monthly)||0.18|
|PE ratio (TTM)||9.84|
|Earnings date||03 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||715.68|
After a series of delays, Pfizer's (PFE) oral JAK inhibitor, Cibinqo (abrocitinib), gets approval for treating adults with atopic dermatitis in the United States.
With that said, let's look at two biotech stocks that have the tools to produce above-average returns over the next decade: Moderna (NASDAQ: MRNA) and Regeneron (NASDAQ: REGN). Moderna was founded in 2010, and it took the company roughly 10 years to finally launch its first product on the market. The wait may have been worth it -- Moderna's COVID-19 vaccine, mRNA-1273, had a fantastic first year on the market.
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.